Industrifonden invests in MinervaX as part of 57MUSD Series B
We are pleased to add MinervaX to the list of our portfolio companies.
Group B Streptococcus (GBS) is a leading cause of sepsis and meningitis in neonates and young infants, resulting in substantial mortality and morbidity. Maternal immunization against GBS would have significant benefits for the prevention of not only neonatal diseases but also GBS-associated stillbirth and preterm delivery. We are delighted to come together with such a strong syndicate to support MinervaX in making GBS diseases vaccine-preventable. We look forward to working with the MinervaX management team and our co-inventors to help accelerate the company’s development ambitiously.
Read more here: https://www.prnewswire.com/news-releases/minervax-raises-upsized-eur-47-4m-usd-57m-series-b-to-advance-its-novel-group-b-streptococcus-vaccine-through-mid-stage-clinical-trials-301192579.html